It's a primarily clinical meeting, but to their credit, they do invite speakers that do primarily basic research. I was talking about our recent discovery, that ADAMTS3 is the activating protease for VEGF-C and the involvement of CCBE1 (here's the abstract of my talk: https://jeltsch.org/sites/jeltsch.org/files/Jeltsch2015_EJLRP.pdf). I proposed that these molecular regulators of lymphangiogenesis could be therapeutic targets, which was met with some scepticism. It is true that we are just at the beginning, but imho, it would be short-sighted to ignore the potential.